Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqASX:IIQ 27 Days Inventory is 212.92 as of Dec. 2025, which is 66% above its 10-year median of 128.58. GuruFocus rates ASX:IIQ with a GF Score™ of 27/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, Inoviq ranks worse than 69.83% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Inoviq's Average Total Inventories for the
six
months ended in Dec. 2025 was A$0.05 Mil. Inoviq's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$0.04 Mil.
Hence, Inoviq's Days Inventory for the
six
months ended in Dec. 2025 was 212.92.
The historical rank and industry rank for Inoviq's Days Inventory or its related term are showing as below:
ASX:IIQ'
s Days Inventory Range Over the Past 10 Years
Min: 81.11 Med: 128.58 Max: 273.75
Current: 114.69
During the past 13 years, Inoviq's highest Days Inventory was 273.75. The lowest was 81.11. And the median was 128.58.
ASX:IIQ's Days Inventory is ranked worse than 69.83% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.04
vs ASX:IIQ: 114.69
Inoviq's Days Inventory
increased
from Dec. 2024 (103.58) to Dec. 2025 (212.92).
It might indicate that Inoviq's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inoviq's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.86.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Inoviq's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.20.
Inoviq (ASX:IIQ) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Inoviq's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Inoviq's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Inoviq Days Inventory Related Terms
Inoviq Days Inventory Historical Data
* Premium members only.
The historical data trend for Inoviq's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IIQ vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Inoviq's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's Days Inventory distribution charts can be found below:
* The bar in red indicates where Inoviq's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inoviq (ASX:IIQ) has a Days Inventory of 212.92 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Inoviq and its competitors. This is 66% above median its historical median of 128.58. Over the past decade, Inoviq's Days Inventory has ranged from 81.11 to 273.75. According to the industry distribution chart, Inoviq ranks #125 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 69.8%.
Is Inoviq's Days Inventory too high?
Inoviq's current Days Inventory of 212.92 is 66% above median its 10-year median of 128.58. Over the past 10 years, this metric has ranged from a low of 81.11 to a high of 273.75. The Medical Diagnostics & Research industry median Days Inventory is 65.04. Inoviq's value of 212.92 is 227.4% above this industry median. Based on the distribution chart, Inoviq ranks #125 out of 179 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Inoviq has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #125 out of 179 companies for Days Inventory. This places Inoviq in the lower half of its industry. The industry median Days Inventory is 65.04. Inoviq's value of 212.92 is 227.4% above this benchmark. Historically, Inoviq's own Days Inventory has ranged from 81.11 to 273.75 over the past decade. While the company's 10-year median is 128.58 vs. the industry median of 65.04, Inoviq has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 65.04, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inoviq's current Days Inventory of 212.92 is 227.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Inoviq and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 65.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inoviq's current Days Inventory is 212.92, which is 66% above median its own 10-year median of 128.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.20 — trading 60.8% below its estimated fair value. The current Days Inventory is 212.92, which is 66% above median its 10-year median of 128.58 and 227.4% above the Medical Diagnostics & Research industry median of 65.04. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current Days Inventory is 212.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (ASX:IIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of A$0.20 is trading 60.8% below its estimated GF Value™ of A$0.51.
GuruFocus considers Inoviq to be Possible Value Trap.
Key valuation signals for ASX:IIQ:
Days Inventory: 212.92 (66% above median its 10-year median of 128.58)
GF Value™: A$0.51 vs. price of A$0.20 (60.8% below fair value)
Industry Position: 227.4% above the Medical Diagnostics & Research median (#125 of 179)
No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score
Get the complete analysis for ASX:IIQ
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IIQ has been successfully added to your 
